Jarrett Simone A, Lo Kevin B, Body Cameron, Kim Joyce J, Zheng Ziduo, Kundu Suprateek, Huang Eugene, Basu Arpita, Flynn Mary, Dietz-Lindo Karan A, Shahnavaz Nikrad, Christie Jennifer
Internal Medicine, Einstein Medical Center Philadelphia, Philadelphia, USA.
Department of Gastroenterology, Wellstar Atlanta, Atlanta, USA.
Cureus. 2022 Apr 19;14(4):e24274. doi: 10.7759/cureus.24274. eCollection 2022 Apr.
Background and objective Multiple comorbidities may contribute to high readmission rates post-transplant procedures. In this study, we aimed to assess the rates and factors associated with hospital readmissions for dyspeptic symptoms among transplant patients. Methods This was a retrospective analysis of adult patients who underwent solid organ transplants at our institution. Pregnant patients or those patients with preexisting gastroparesis were excluded from the study. Readmissions associated with the International Classification of Diseases (ICD) codes for nausea/vomiting, weight loss, failure to thrive, abdominal pain, and/or bloating were included. Factors associated with 30-day and frequent readmissions (two or more) were explored. Results A total of 931 patients with solid organ transplants were included; 54% had undergone kidney transplants while 34% were liver transplants. Of note, 30% were readmitted within the first 30 days after discharge following transplant while 32.3% had frequent readmissions. A post-transplant upper endoscopy (EGD) was performed in 34% with food residue discovered in 19% suggesting gastroparesis. However, since only 22% of these patients had a gastric emptying study, only 6% were formally diagnosed with gastroparesis, which was independently associated with both 30-day [odds ratios (OR): 2.58, 95% confidence intervals (CI): 1.42-4.69] and frequent readmissions (OR: 6.71, 95% CI: 3.45-13.10). The presence of pre-transplant diabetes (35%) was significantly associated with a diagnosis of gastroparesis following transplant (OR: 5.17, 95% CI: 2.79-9.57). The use of belatacept (OR: 0.63, 95% CI: 0.42-0.94, p=0.023) was associated with a decrease in the odds of 30-day readmissions. Conclusion A significant number of patients were readmitted due to dyspeptic symptoms after solid organ transplants. Diabetes and gastroparesis were significantly associated with higher odds of readmissions while the use of belatacept appeared to be a protective factor.
多种合并症可能导致移植手术后的高再入院率。在本研究中,我们旨在评估移植患者因消化不良症状再次入院的发生率及相关因素。方法:这是一项对在我们机构接受实体器官移植的成年患者的回顾性分析。怀孕患者或已有胃轻瘫的患者被排除在研究之外。纳入与国际疾病分类(ICD)编码中恶心/呕吐、体重减轻、发育不良、腹痛和/或腹胀相关的再入院情况。探究与30天内再入院及频繁再入院(两次或更多次)相关的因素。结果:共纳入931例实体器官移植患者;54%接受了肾移植,34%接受了肝移植。值得注意的是,30%的患者在移植出院后的前30天内再次入院,32.3%的患者频繁再入院。34%的患者进行了移植后上消化道内镜检查(EGD),19%发现有食物残留,提示胃轻瘫。然而,由于这些患者中只有22%进行了胃排空研究,只有6%被正式诊断为胃轻瘫,胃轻瘫与30天内再入院(比值比(OR):2.58,95%置信区间(CI):1.42 - 4.69)和频繁再入院(OR:6.71,95% CI:3.45 - 13.10)均独立相关。移植前糖尿病的存在(35%)与移植后胃轻瘫的诊断显著相关(OR:5.17,95% CI:2.79 - 9.57)。使用贝拉西普(OR:0.63,95% CI:0.42 - 0.94,p = 0.023)与30天内再入院几率的降低相关。结论:大量实体器官移植患者因消化不良症状再次入院。糖尿病和胃轻瘫与再入院几率较高显著相关,而使用贝拉西普似乎是一个保护因素。